11:31:56 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-07 Kvartalsrapport 2024-Q3
2024-08-15 Kvartalsrapport 2024-Q2
2024-05-16 Kvartalsrapport 2024-Q1
2024-03-21 X-dag ordinarie utdelning ZEAL 0.00 DKK
2024-03-20 Årsstämma 2024
2024-02-27 Bokslutskommuniké 2023
2023-11-09 Kvartalsrapport 2023-Q3
2023-08-17 Kvartalsrapport 2023-Q2
2023-05-11 Kvartalsrapport 2023-Q1
2023-03-30 X-dag ordinarie utdelning ZEAL 0.00 DKK
2023-03-29 Årsstämma 2023
2023-03-02 Bokslutskommuniké 2022
2022-11-10 Kvartalsrapport 2022-Q3
2022-08-11 Kvartalsrapport 2022-Q2
2022-05-12 Kvartalsrapport 2022-Q1
2022-05-09 X-dag ordinarie utdelning ZEAL 0.00 DKK
2022-04-06 Årsstämma 2022
2022-03-10 Bokslutskommuniké 2021
2021-11-11 Kvartalsrapport 2021-Q3
2021-08-12 Kvartalsrapport 2021-Q2
2021-05-12 Kvartalsrapport 2021-Q1
2021-04-16 X-dag ordinarie utdelning ZEAL 0.00 DKK
2021-04-15 Årsstämma 2021
2021-03-11 Bokslutskommuniké 2020
2020-11-12 Kvartalsrapport 2020-Q3
2020-08-13 Kvartalsrapport 2020-Q2
2020-05-14 Kvartalsrapport 2020-Q1
2020-04-03 X-dag ordinarie utdelning ZEAL 0.00 DKK
2020-04-02 Årsstämma 2020
2020-03-12 Bokslutskommuniké 2019
2019-11-14 Kvartalsrapport 2019-Q3
2019-08-15 Kvartalsrapport 2019-Q2
2019-05-16 Kvartalsrapport 2019-Q1
2019-04-05 X-dag ordinarie utdelning ZEAL 0.00 DKK
2019-04-04 Årsstämma 2019
2019-03-07 Bokslutskommuniké 2018
2018-11-15 Kvartalsrapport 2018-Q3
2018-08-16 Kvartalsrapport 2018-Q2
2018-05-16 Kvartalsrapport 2018-Q1
2018-04-20 X-dag ordinarie utdelning ZEAL 0.00 DKK
2018-04-19 Årsstämma 2018
2018-03-07 Bokslutskommuniké 2017
2017-11-08 Kvartalsrapport 2017-Q3
2017-08-24 Kvartalsrapport 2017-Q2
2017-05-17 Kvartalsrapport 2017-Q1
2017-04-06 X-dag ordinarie utdelning ZEAL 0.00 DKK
2017-04-05 Årsstämma 2017
2017-03-15 Bokslutskommuniké 2016
2016-11-09 Kvartalsrapport 2016-Q3
2016-08-25 Kvartalsrapport 2016-Q2
2016-05-18 Kvartalsrapport 2016-Q1
2016-04-20 X-dag ordinarie utdelning ZEAL 0.00 DKK
2016-04-19 Årsstämma 2016
2016-03-16 Bokslutskommuniké 2015
2015-11-05 Kvartalsrapport 2015-Q3
2015-08-28 Kvartalsrapport 2015-Q2
2015-05-22 Kvartalsrapport 2015-Q1
2015-04-22 X-dag ordinarie utdelning ZEAL 0.00 DKK
2015-04-21 Årsstämma 2015
2015-03-12 Bokslutskommuniké 2014
2014-11-07 Kvartalsrapport 2014-Q3
2014-08-21 Kvartalsrapport 2014-Q2
2014-05-06 Kapitalmarknadsdag 2014
2014-04-29 Kvartalsrapport 2014-Q1
2014-04-29 Årsstämma 2014
2014-03-21 X-dag ordinarie utdelning ZEAL 0.00 DKK
2014-03-20 Bokslutskommuniké 2013
2013-11-15 Kvartalsrapport 2013-Q3
2013-08-29 Kvartalsrapport 2013-Q2
2013-05-15 Kvartalsrapport 2013-Q1
2013-04-30 Årsstämma 2013
2013-04-30 X-dag ordinarie utdelning ZEAL 0.00 DKK
2013-03-14 Bokslutskommuniké 2012
2012-11-29 Kapitalmarknadsdag 2012
2012-04-26 X-dag ordinarie utdelning ZEAL 0.00 DKK
2012-04-25 Årsstämma 2012
2011-11-17 Kvartalsrapport 2011-Q3
2011-10-25 Kapitalmarknadsdag 2011
2011-08-18 Kvartalsrapport 2011-Q2
2011-05-12 Kvartalsrapport 2011-Q1
2011-04-29 X-dag ordinarie utdelning ZEAL 0.00 DKK
2011-04-28 Årsstämma 2011

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriBioteknik
Zealand Pharma är verksamt inom bioteknik. Särskilt fokus återfinns inom utvecklingen av läkemedel för behandling av diabetes och diverse tarmsjukdomar. Bolaget innehar en varierad produktportfölj med separata varumärken som säljs på global nivå. Störst verksamhet finns inom den nordiska marknaden. Zealand Pharma grundades 1997 och har sitt huvudkontor i Söborg, Danmark.
2021-08-31 17:00:00

Company announcement – No. 54 / 2021

Total number of shares and voting rights in Zealand Pharma at August 31, 2021

Copenhagen, DK and Boston, MA, August 31, 2021 Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital.  

In Company announcement No. 53/2021 from August 20, 2021, Zealand announced an increase in share capital relating to the exercise of employee warrants. Following this announcement, the table below lists the total number of shares and voting rights in Zealand up to and including August 31, 2021.



Date
Number of shares
(nominal value of DKK 1 each)
Share capital
(nominal value in DKK)
Number of voting rights
August 31, 202143,550,94943,550,94943,550,949


# # #

About Zealand Pharma A/S 

Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. Zealand markets V-Go®, a basal-bolus insulin delivery option for people with diabetes, and Zegalogue®, (dasiglucagon), the first and only glucagon analogue for the treatment severe hypoglycemia in pediatric and adult patients with diabetes aged 6 and above. To support these two marketed products Zealand built a dedicated sales force in the United States and has established itself as a fully integrated biotechnology company.  In addition, license collaborations with Boehringer Ingelheim and AstraZeneca create opportunities for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development.

Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit http://www.zealandpharma.com

Forward-Looking Statement
The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.

For further information, please contact:

Zealand Pharma Investor Relations
Claudia Styslinger
Argot Partners
investors@zealandpharma.com 


Zealand Pharma Media Relations
David Rosen
Argot Partners
media@zealandpharma.com